C Ray Therapeutics Expands Radiopharma Role With Isotope Supply, Automation, and Localized Alpha Therapy Focus

C Ray Therapeutics, a China-based radiopharmaceutical CRDMO, spent the week spotlighting its role in solving key bottlenecks in targeted alpha therapy, from isotope supply to advanced manufacturing. The company positioned itself as a strategic connector between Western isotope producers and rapidly expanding Asian radiopharma capacity, with a prominent convening role at the XDC Conference 2026 in Chengdu.

Across several updates, C Ray highlighted NorthStar Medical Radioisotopes’ efforts to scale Actinium-225 production and co-located CDMO services, aiming to reduce logistics-driven decay losses and what it calls the “decay tax.” The firm framed reliable Ac-225 and Cu-67 supply as critical to moving promising radioantibody and theranostic programs from clinical success toward commercial viability.

The company also drew attention to Lead-212 supply challenges, citing more than 80 Pb-212 assets in development and the half-life and logistics constraints that limit broad adoption. It showcased Thor Medical ASA’s “Thorium-to-Therapy” model, which uses reactor-free extraction of alpha emitters from thorium decay chains to enable decentralized, high-purity Pb-212 production, a concept seen as particularly relevant for Asian markets.

On the technology front, C Ray underscored partnerships with TRUKING TECHNOLOGY LIMITED and STÄUBLI, emphasizing Stericlean robotic systems for GMP-compliant aseptic radiopharmaceutical production. These automation initiatives are intended to support scalable manufacturing of radioligand therapies involving isotopes such as Ac-225 and Lu-177, enhancing quality, reliability, and regulatory alignment.

Strategically, the company continued to promote localized alpha therapies for peritoneal metastases using Ra-224, arguing that delivery geometry, not just drug potency, is key for treating micrometastases in ovarian and gastrointestinal cancers. Through co-organization of the International RDC Sub-Forum at XDC 2026 and industry participation in Boston, C Ray is reinforcing its thought leadership while strengthening infrastructure like its AAALAC-accredited Chengdu facility.

Taken together, the week’s communications indicate C Ray Therapeutics is deepening its positioning as a platform partner across the radiopharmaceutical value chain, from isotope sourcing and logistics to automated GMP manufacturing and specialized alpha therapy strategies. While specific financial metrics and pipeline milestones remain limited, these moves could support future partnerships and bolster the company’s long-term competitiveness in nuclear medicine and targeted oncology.